Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph S Ross

Showing results (111-120 of 800) with videos related to

Pageof 80
Sort By:
BMJ (Clinical Research Ed.)|October 5, 2022
Spontaneous reporting of post-market safety signals: what evidence should support regulatory action?Meera M Dhodapkar, Joseph S Ross, Reshma Ramachandran
Journal of Clinical Epidemiology|January 29, 2016
Compliance with prospective trial registration guidance remained low in high-impact journals and has implications for primary end point reportingRafael Dal-Ré, Joseph S Ross, Ana Marušić
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|October 19, 2021
Alexander C Egilman, Joseph S Ross, Matthew Herder
Clinical Trials (London, England)|June 7, 2018
The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvementsJoshua D Wallach, Joseph S Ross, Huseyin Naci
Health Affairs (Project Hope)|April 8, 2015
Efficacy and safety concerns are important reasons why the FDA requires multiple reviews before approval of new drugsJoseph S Ross, Kristina Dzara, Nicholas S Downing
Research Integrity and Peer Review|January 9, 2020
Impact of US industry payment disclosure laws on payments to surgeons: a natural experimentTaeho Greg Rhee, Tijana Stanic, Joseph S Ross
The New England Journal of Medicine|October 27, 2022
Medicare's National Coverage Determination for Aducanumab - A One-Off or a Pragmatic Path Forward?Sanket S Dhruva, Reshma Ramachandran, Joseph S Ross
The New England Journal of Medicine|September 11, 2023
The Accelerated Approval Program for Cancer Drugs - Finding the Right BalanceBishal Gyawali, Aaron S Kesselheim, Joseph S Ross
JAMA Health Forum|June 20, 2025
Public Health Implications of Legal Challenges to the FDA's Regulation of Laboratory-Developed TestsKushal T Kadakia, Joseph S Ross, Reshma Ramachandran
BMJ (Clinical Research Ed.)|May 16, 2022
Generating evidence during a pandemic: what's reliable?Joshua D Wallach, Osman Moneer, Joseph S Ross
Pageof 80

Showing results (111-120 of 800) with videos related to

Sort By:
Pageof 80
BMJ (Clinical Research Ed.)|October 5, 2022
Spontaneous reporting of post-market safety signals: what evidence should support regulatory action?Meera M Dhodapkar, Joseph S Ross, Reshma Ramachandran
Journal of Clinical Epidemiology|January 29, 2016
Compliance with prospective trial registration guidance remained low in high-impact journals and has implications for primary end point reportingRafael Dal-Ré, Joseph S Ross, Ana Marušić
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|October 19, 2021
Alexander C Egilman, Joseph S Ross, Matthew Herder
Clinical Trials (London, England)|June 7, 2018
The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvementsJoshua D Wallach, Joseph S Ross, Huseyin Naci
Health Affairs (Project Hope)|April 8, 2015
Efficacy and safety concerns are important reasons why the FDA requires multiple reviews before approval of new drugsJoseph S Ross, Kristina Dzara, Nicholas S Downing
Research Integrity and Peer Review|January 9, 2020
Impact of US industry payment disclosure laws on payments to surgeons: a natural experimentTaeho Greg Rhee, Tijana Stanic, Joseph S Ross
The New England Journal of Medicine|October 27, 2022
Medicare's National Coverage Determination for Aducanumab - A One-Off or a Pragmatic Path Forward?Sanket S Dhruva, Reshma Ramachandran, Joseph S Ross
The New England Journal of Medicine|September 11, 2023
The Accelerated Approval Program for Cancer Drugs - Finding the Right BalanceBishal Gyawali, Aaron S Kesselheim, Joseph S Ross
JAMA Health Forum|June 20, 2025
Public Health Implications of Legal Challenges to the FDA's Regulation of Laboratory-Developed TestsKushal T Kadakia, Joseph S Ross, Reshma Ramachandran
BMJ (Clinical Research Ed.)|May 16, 2022
Generating evidence during a pandemic: what's reliable?Joshua D Wallach, Osman Moneer, Joseph S Ross
Pageof 80